EMA clears Oryzon to launch HOPE-2 Phase II vafidemstat trial in Phelan-McDermid syndrome

• EMA cleared Oryzon Genomics to start the Phase IIa HOPE-2 trial of vafidemstat in Phelan-McDermid syndrome.
• Open-label, single-center study targets 12 adults in Spain, with 12 weeks of dosing and an option to extend to 24 weeks.
• Trial is partly funded through Oryzon’s VANDAM project under the EU-backed Med4Cure IPCEI health program.
• Spain’s Ministry of Science, Innovation and Universities, CDTI, and the EU’s NextGenerationEU are providing the public funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.